High glucose stimulated the expression of PAI-1 in VSMCs by activating two Sp1-binding sites at the promoter region of the PAI-1 gene (23). diabetes on cardiovascular function as well as mediating the response to ischemic injury. Here, we summarize our present understanding of proteinO-GlcNAcylation and TGR-1202 hydrochloride its effect on the regulation of cardiovascular function. We examine the pathways regulating proteinO-GlcNAcylation and discuss, in more TGR-1202 hydrochloride detail, our understanding of the role ofO-GlcNAc in both mediating the adverse effects of diabetes as well as its role in mediating cellular protective mechanisms in the cardiovascular system. In addition, we also explore the parallels betweenO-GlcNAc signaling and redox signaling, as an alternative paradigm for understanding the role ofO-GlcNAcylation in TGR-1202 hydrochloride regulating cell function. Keywords:hexosamine biosynthesis, proteinO-glycosylation, -N-acetylglucosamine transferase, diabetes mellitus posttranslational modification(PTM) of proteins is usually a common mechanism for the modulation of protein function, location, and turnover. Although protein phosphorylation is probably the most widely analyzed form of PTM, there are many other PTMs, including acylation, ubiquitylation, methylation, acetylation, thiolation, nitration, and glycosylation (107). The focus of this evaluate is protein glycosylation, specifically,O-glycosylation of nuclear and cytoplasmic proteins. Classical protein glycosylation occurs in the endoplasmic reticulum and Golgi, leading to the formation of stable and complex elongated oligosaccharide structures via bothN-linkage on asparagine andO-linkage around the hydroxy amino acids serine and threonine in addition to hydroxyproline, hydroxylysine, and tyrosine residues of proteins that become secreted or membrane component glycoproteins (189). In contrast, glycosylation of nuclear and cytoplasmic proteins is a rapid and dynamic modification of serine or threonine residues by theO-linked attachment of the monosaccharide -N-acetylglucosamine (O-GlcNAc) (97,195); this process is referred to as proteinO-GlcNAcylation to contrast it with traditionalN- andO-glycosylation within the secretory pathways. The modification of serine/threonine residues byO-GlcNAc was first recognized by Torres and Hart in 1984 (195).O-GlcNAcylation is a highly dynamic and IKK-alpha ubiquitous PTM that plays a role in altering the function (121), activity (59), subcellular localization (57,73,219), and stability of target proteins (84,229).O-GlcNAcylation is often considered analogous to phosphorylation (88) in that it is a tightly regulated enzyme-catalyzed process that leads to the modification of specific serine/threonine residues, which, in many cases, are also subject to phosphorylation. However, there are also some unique differences between these two types of PTMs. For example, in contrast to the hundreds of kinases and phosphatases that regulate protein phosphorylation, to date, only one enzyme has been recognized that catalyzes the formation ofO-GlcNAc and one enzyme that catalyzes its removal, which raises questions regarding the requirements of the biological regulation of the specificity ofO-GlcNAcylation. In this review, we also explore the TGR-1202 hydrochloride possibility that theO-GlcNAc pathway has much in common with redox cell signaling pathways that arise from the modification of specific reactive cysteine residues on proteins. ProteinO-GlcNAcylation is usually rapidly emerging as a key regulator of crucial biological processes, such as nuclear transport (77), translation and transcription (30), transmission transduction (139,183,225,226), cytoskeletal reorganization (42,87), proteasomal degradation (83,227), and apoptosis (138,208). Much of our present knowledge regarding the role ofO-GlcNAcylation on cellular function is in the context of chronic diseases, including senescence (62,64,177), malignancy (27,47,182), and neurodegenerative disorders such as Alzheimer’s disease (45,85,139,208). Sustained increases ofO-GlcNAc have been implicated as a pathogenic contributor to glucose toxicity and insulin resistance (15,33), which are major hallmarks of diabetes mellitus and diabetes-related vascular complications. However, in contrast to these adverse effects, there is a growing body of data supporting the beneficial role ofO-GlcNAc in mediating cellular protection designed to enhance cell survival. Reports on the effect of alteredO-GlcNAc levels around the heart and cardiovascular system have been growing rapidly over the past few years and TGR-1202 hydrochloride have implicated a role forO-GlcNAc in mediating the response to ischemic injury as well as contributing to the adverse effects of diabetes on cardiac and vascular function. The goal of this review is usually to summarize our present understanding of proteinO-GlcNAcylation and its effect on the regulation of cardiovascular function. We provide information regarding the pathways regulating proteinO-GlcNAcylation and discuss, in more detail, our understanding of the role ofO-GlcNAc in both mediating the adverse effects of diabetes as well as its role in mediating cellular protective mechanisms in the cardiovascular system. In addition, we also examine the parallels betweenO-GlcNAc signaling and redox signaling as an alternative paradigm for understanding the role ofO-GlcNAcylation in regulating cell function. == The Hexosamine Biosynthesis Pathway == It is estimated from in vitro cell culture studies that between 2% and 5% of total glucose entering the cell is usually metabolized via the hexosamine biosynthesis pathway (HBP;Fig. 1) (148). Glucose entry into the HBP is regulated byl-glutamine-d-fructose 6-phosphate amidotransferase (GFAT), which converts fructose-6-phosphate to glucosamine-6-phosphate with glutamine.
High glucose stimulated the expression of PAI-1 in VSMCs by activating two Sp1-binding sites at the promoter region of the PAI-1 gene (23)